EasyOne products provide advanced protection for patients and medical staff in clinical and research settings
Andover, MA – 21 July 2020. ndd Medical Technologies (ndd), a leading provider of diagnostic technology enabling healthcare professionals the early detection of COPD and other chronic lung diseases, has introduced new single patient-use, inline filters for its lung function testing devices, in response to the global COVID-19 pandemic. Ensuring an added level of safety, the new filters can be used with ndd’s revolutionary, and highly portable EasyOne® spirometry range, including the EasyOne Air, EasyOne Pro, and EasyOne Pro LAB. EasyOne spirometers are popular among pulmonologists and medical researchers as they are of the most sensitive devices available, delivering reliable, real-time lung function results and diagnosis of chronic lung diseases, even at the point of care.
COVID-19 has had a massive impact on global healthcare systems, and the safety of both patients and healthcare professionals during lung function testing is paramount.1 In addition, as the SARS-CoV-2 virus is known to affect the lungs, there is growing research into the effects of COVID-19 on lung function post-infection.2
The EasyOne product line was originally designed with a strong focus on infection control with easy-to-wipe surfaces, single-use parts for anything that comes into contact with a patient’s breath, and ndd’s unique spirette and flow tube design which protects the flow sensor from cross-contamination. Now, when performing spirometry and testing of the diffusing capacity of the lungs for carbon monoxide (DLCO tests), the new EasyOne inline, single patient-use filters provide “double protection” for technicians and patients by keeping the ambient environment clean, without significantly affecting the EasyOne’s sensitivity.3
Leading pulmonologists and medical researchers around the world use ndd’s lung function testing products due to portability, which means they can easily be used in point of care settings, and because they are of the most sensitive devices available. ndd’s rigorous sensitivity tests have shown that the new inline filters do not significantly affect this sensitivity and show comparable results in 24 waveform testing, (as required by ATS/ERS) and pass testing requirements3. World-renowned medical research organizations—such as Johns Hopkins University, University Hospital Zurich and University of Cape Town—are partnering with ndd to assess the long-term lung damage caused by SARS-CoV-2.
Dr Trishul Siddharthan, Assistant Professor of Pulmonary and Critical Care Medicine at Johns Hopkins University, commented, “There is a lot of research underway to investigate the long-term effects of COVID-19. Our research group has been partnering with ndd thanks to the reliability of these spirometers in global settings and the ease of cleaning these devices during the pandemic to ensure safety.”
Prof. Friedrich Thienemann, General Medicine & Global Health research group, University of Cape Town and University Hospital Zurich, also noted, “In order to measure lung functions in resource-constraint settings like South African townships, one needs a device that is portable, point-of-care, easy-to-use, low-maintenance, and reliable without complicated calibration. EasyOne Pro LAB is that device.”
Incorporating ndd’s patented TrueFlowTM ultrasound technology, the EasyOne translates airflow into ultrasound signals which are measured by the sensors, so the patient’s breath does not come into contact with the sensors. This helps to prevent contamination and minimizes the cleaning required for safe use, while enabling a lifetime of calibration-free accuracy for flow and volume measurements.
Georg Harnoncourt, ndd Medical’s CEO, commented: “At ndd we have always designed our lung function testing products with safety in mind, so since the onset of the COVID-19 pandemic, we have worked tirelessly to develop additional infection control measures to protect both technicians and patients. Our EasyOne spirometers already offer superior infection control as everything that comes into contact with a person’s breath is replaced after use. In addition, our new inline filters have been carefully designed and tested so that, in combination with this superior infection control design, you can continue critical lung function testing during the COVID-19 pandemic as safely as possible.”
To learn more about EasyOne inline filter solutions or for order inquiries, please click here. For more information about ndd’s lung function testing products, please visit www.nddmed.com.
References
- Hull J, Lloyd J, Cooper B. Lung function testing in the COVID-19 endemic. The Lancet Respiratory Medicine. 2020;20.
- Mo X, Jian W, Su Z, Chen M, Peng H, Peng P et al. Abnormal pulmonary function in COVID-19 patients at time of hospital discharge. European Respiratory Journal. 2020;55(6):2001217.
- ndd Medical. Internal data on file. 2020.
Editor’s notes
About ndd Medical Technologies
Founded in 1992 by Professor Karl Harnoncourt, ndd Medical Technologies Inc. is the global leader and innovator in lung function testing and PFT devices. For more than 20 years, ndd has worked to improve the early detection and accurate diagnosis for people living with COPD and other chronic lung diseases with EasyOne products—by supporting research, helping to create awareness and launching innovative products and making them available to over 100 countries.
The EasyOne product line was developed for physicians to offer accurate and reliable diagnosis at the point of care and start immediate treatment. This helps avoid irreversible lung damage for millions of patients while significantly reducing healthcare costs.
Find out more at www.nddmed.com.